Biotech investment draws political controversy – picking favorites perceived as undermine public efforts and a corporate handout
Servick 19 [Kelly Servick is a staff writer at Science, "Controversial U.S. bill would lift Supreme Court ban on patenting human genes", Science, https://www.science.org/content/article/controversial-us-bill-would-lift-supreme-court-ban-patenting-human-genes] GBS-HW
A congressional proposal that would overturn a landmark U.S. Supreme Court decision that barred the patenting of human genes and ease other restrictions on patenting software and biomedical inventions is drawing fierce criticism from some scientific societies and patient advocates. Yesterday, the American Civil Liberties Union (ACLU) in Washington, D.C., along with more than 100 other signatories from research institutes and advocacy groups, released a letter to lawmakers arguing the changes would stifle medical research and hinder patients' access to diagnostic tests.
The draft bill "would result in a quagmire of patent claims and legal impediments to the normal scientific exchange," said Harold Varmus, a cancer biologist at Weill Cornell Medicine in New York City and former director of the National Cancer Institute, in a press conference yesterday. "It's in the interest of virtually everyone to keep ideas and basic discoveries about the laws and products of nature in the public domain."
The ACLU letter comes as the Senate Committee on the Judiciary kicks off the first in a series of three hearings that will examine potential changes to U.S. patent law. Today's hearing is expected to include discussion of the draft proposal, released last month by a bipartisan group of lawmakers, which would overturn current restrictions on patenting products and processes that occur in nature, including human genes.
The bill aims to address a complaint that has been brewing for years in the biotechnology and software industries: that recent Supreme Court decisions have created confusing and overly stringent patent eligibility rules. In particular, critics point to three recent rulings:
The 2012 decision in Mayo Collaborative Services v. Prometheus Laboratories invalidated a patent on adjusting drug dosage based on levels of metabolites in a patient's blood because it relied on a "law of nature."
The landmark 2013 ruling in Association for Molecular Pathology (AMP) v. Myriad Genetics Inc. said that human genes can't be patented because they are a "product of nature."
In 2014, software patents took a blow from the Alice Corp. v. CLS Bank International decision, which found a financial trading program to be an unpatentable "abstract idea."
The new bill "makes it clear in no uncertain terms that all the Supreme Court [decisions] are just gone," says Arti Rai, a patent law expert at Duke University in Durham, North Carolina. It says decisions about patent eligibility should not rely on "judicially created exceptions … including ‘abstract ideas,' ‘laws of nature,' or ‘natural phenomena.'"
The bill's sponsors in the Senate, Thom Tillis (R–NC) and Chris Coons (D–DE), have described it as a way to restore incentives for U.S. innovation by making the process for protecting new inventions more predictable. (Competition with China, where no comparable restrictions exist in the patent system, may have motivated the lawmakers, Rai says.)
But opponents say the bill would enable monopolies on discoveries that should be widely available for research and medical use. In the 2013 Myriad case, the diagnostic company Myriad Genetics of Salt Lake City claimed that its broad patents on two human genes gave it exclusive rights to clinical tests for cancer-associated mutations in those genes. In striking down the patents, the Supreme Court allowed other diagnostic companies to offer such tests without fear of infringement lawsuits. Signatories on the new letter—including plaintiffs who challenged the Myriad patents, and ACLU, which represented them—argue that if the proposed law is enacted, "We will again see high prices for tests with no competition in the market."